US biotech company Moderna on Wednesday announced positive results for a new vaccine that targets both the original Covid strain and Omicron.
This so-called “bivalent” vaccine was tested in a trial of more than 850 adults, who had all received their first three doses of Moderna’s original Spikevax vaccine.
Around half the group then received a fourth dose of Spikevax, while the rest received the bivalent vaccine.
Those who received the bivalent vaccine had significantly higher levels of neutralizing antibodies — Y-shaped immune system proteins that block the virus — against Omicron.
On average, these levels were around 75 per cent higher in the group who got the bivalent vaccine as a fourth dose compared to those who got the original vaccine as a fourth dose. They also received slightly superior protection to the ancestral strain of Covid compared to Spikevax.
“We are thrilled,” said Stephane Bancel, CEO of Moderna in a statement, adding he anticipated this vaccine would be the company’s lead candidate for authorization as a booster this fall.
“We want to be as ready as early as August for shipping,” he told investors in a call.
Stephen Hoge, the company’s president, did concede that antibody levels would be lower against Omicron’s sub variants that are now in circulation, but said he believed it was still a superior booster than repeating Spikevax.
The company doesn’t yet have data on durability — how the new vaccine booster will fare three months and six months out.
A panel of Food and Drug Administration experts will meet June 28 to discuss considerations and strategies for boosters in fall and winter.